Dermira (NASDAQ:DERM) had its price target cut by Leerink Swann from $23.00 to $15.00 in a research note published on Tuesday, The Fly reports. They currently have an outperform rating on the biopharmaceutical company’s stock.
A number of other research firms have also recently issued reports on DERM. Zacks Investment Research upgraded shares of Dermira from a hold rating to a strong-buy rating and set a $6.50 price objective for the company in a research report on Wednesday, October 9th. BidaskClub upgraded shares of Dermira from a strong sell rating to a sell rating in a research report on Saturday, October 19th. Finally, Needham & Company LLC reiterated a buy rating and set a $22.00 price objective on shares of Dermira in a research report on Friday, October 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $17.12.
Shares of Dermira stock traded up $1.26 during trading on Tuesday, hitting $8.23. 8,524,000 shares of the stock were exchanged, compared to its average volume of 1,234,329. The company has a fifty day moving average price of $6.66 and a 200-day moving average price of $8.60. The stock has a market capitalization of $368.00 million, a price-to-earnings ratio of -1.57 and a beta of 1.33. The company has a current ratio of 8.42, a quick ratio of 8.08 and a debt-to-equity ratio of 4.95. Dermira has a 1-year low of $5.25 and a 1-year high of $15.48.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.34. The business had revenue of $11.53 million during the quarter, compared to analysts’ expectations of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 485.60%. Equities research analysts forecast that Dermira will post -4.42 EPS for the current fiscal year.
In other Dermira news, CEO Thomas G. Wiggans purchased 23,419 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was purchased at an average cost of $8.54 per share, for a total transaction of $199,998.26. Following the transaction, the chief executive officer now owns 39,666 shares in the company, valued at approximately $338,747.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Matthew K. Fust sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $8.77, for a total transaction of $52,620.00. Following the completion of the transaction, the director now owns 11,051 shares of the company’s stock, valued at $96,917.27. The disclosure for this sale can be found here. 12.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Hong Kong Ltd increased its position in Dermira by 124.2% in the 2nd quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 2,310 shares during the period. Bank of Montreal Can increased its position in Dermira by 621.8% in the 2nd quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 3,905 shares during the period. Advisor Group Inc. increased its position in Dermira by 41.7% in the 2nd quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 2,527 shares during the period. Atria Investments LLC acquired a new position in Dermira in the 2nd quarter valued at approximately $85,000. Finally, Oppenheimer Asset Management Inc. increased its position in Dermira by 12.3% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 18,552 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 2,031 shares during the period. Hedge funds and other institutional investors own 94.34% of the company’s stock.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Read More: High-Yield Dividend Stocks
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.